Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC May 15, 2023 Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... September 8, 2025 Increasing Education About Cancer Screening and Prevention in Kazakhstan May 11, 2021 4 Ways to Manage Setbacks in Your Cancer Recovery: A Young... April 11, 2023 Load more HOT NEWS New on NCI’s Websites for November 2024 What can elephants teach us about cancer? Pink Van Makes the Rounds Throughout Rural New Zealand to Offer... Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information
